Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024. 

"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."

Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month. 

The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses. 

Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent. 

Share:
More In Business
Verizon is Planning to Expand 5G Network in Rural Areas
Verizon is taking steps to speed up its 5G network in rural areas. The company said it plans to extend its C-band 5G network across a larger suburban and rural footprint, meaning faster speeds for customers in those areas.
Elizabeth Holmes Delays Going to Prison With Another Appeal
Disgraced Theranos CEO Elizabeth Holmes has avoided starting her more than 11-year prison sentence on Thursday by deploying the same legal maneuver that enabled her co-conspirator in a blood-testing hoax to remain free for an additional month.
Stretching Your Dollar: Benefits of Cash as an Asset Class
When people think of asset classes, most think of stocks and bonds. Mark Hamrick, senior economic analyst with Bankrate.com, joined Cheddar News to discuss why the current economy is making the cash savings account a more worthwhile investment than it's been in previous years.
Load More